NovoCure Ltd (NovoCure) carries out the discovery, development and marketing of novel Tumor Treating Fields (TTF) delivery systems for the treatment of aggressive cancers of brain and abdomen. The company has two marketed products: Optune Lua and Optune Gio. For Optune Lua, the company obtained the US Food and Drug Administration’s (FDA) approval under Humanitarian Device Exemption (HDE) pathway for the treatment of malignant pleural mesothelioma (MPM) in combination with standard chemotherapies.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

NovoCure is advancing product development and clinical programs to improve the survival of patients suffering from pancreatic cancer, brain metastases, glioblastoma, and non-small cell lung cancer. It is advancing pipeline programs in the final pending phase: Trident for the treatment of glioblastoma; Keynote B36 and Lunar-2 for the treatment of non-small cell lung cancer; Panova-3 and Panova-4 for pancreatic cancer and Metis for the treatment of brain metastases. In FY2023, the company spent US$223.1 million on its R&D activities, which grew 8.2% YoY. NovoCure's intellectual property portfolio consists of several issued patents and pending patent applications worldwide.